Does the new formulation of oxycontin® deter misuse? A qualitative analysis

Substance Use and Misuse

Volumn 49, Issue 6, 2014, Pages 770-774

  Buer, Lesly Marie ^a   Havens, Jennifer R ^a   Leukefeld, Carl ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Misuse deterrence; OxyContin ; Prescription drug; Rural

Indexed keywords

OXYCODONE;

ADULT; CHEMISTRY; EPIDEMIOLOGY; FEMALE; HUMAN; MALE; MEDICINAL CHEMISTRY; QUALITATIVE RESEARCH; RURAL POPULATION; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

ADULT; CHEMISTRY, PHARMACEUTICAL; FEMALE; HUMANS; KENTUCKY; MALE; OXYCODONE; QUALITATIVE RESEARCH; RURAL POPULATION; SUBSTANCE-RELATED DISORDERS;

EID: 84897501302     PISSN: 10826084     EISSN: 15322491     Source Type: Journal    
DOI: 10.3109/10826084.2013.866963     Document Type: Article

References (30)

1. Anglin, M. K., & White, J. C. (1999). Poverty, health care, and problems of prescription medication: a case study. Substance Use Misuse, 34(14), 2073-2093.
2. Appalachian Regional Commission. (2011). County Economic Status and Number of Distressed Areas in Appalachian Kentucky, Fiscal Year 2012. Retrieved from http://www.arc.gov/images/appregion/economic-statusFY2012/CountyEconomic StatusndDistressAreasFY2012Kentucky.pdf
3. Barendregt, C, van der Poel, A., & van de Mheen, D. (2005). Tracing selection effects in three non-probability samples. European Addiction Research, 11(3), 124-131.
4. Cicero, T. J., Inciardi, J. A., & Muñoz, A. (2005). Trends in abuse of OxyContin® and other opioid analgesics in the United States: 2002-2004. Journal of Pain, 6(10), 662-672.
5. Davis, M. P., Varga, J., Dickerson, D., Walsh, D., LeGrand, S. B., & Lagman, R. (2003). Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Supportive Care in Cancer, 11(2), 84-92.
6. Dew, B., Elifson, K., & Dozier, M. (2007). Social and environmental factors and their infuence on drug use vulnerability and resiliency in rural populations. Journal of Rural Health, 23(S1), 16-21.
7. Havens, J. R., Oser, C. B., Leukefield, C. G., Webster, J. M., Martin, S. S., O'Connell, D. J., et al. (2007a). Differences in prevalence of prescription opiate misuse among rural and urban probationers. American Journal of Drug and Alcohol Abuse, 33(2), 309-317.
8. Havens, J. R., Walker, R., & Leukefield, C. G. (2007b). Prevalence of opioid analgesic injection among rural nonmedical opioid analgesic users. Drug and Alcohol Dependence, 87(1), 98-102.
9. Havens, J. R., Walker, R., & Leukefield, C. G. (2008). Prescription opioid use in rural Appalachia: A community based study. Journal of Opioid Management, 4(2), 63-71.
10. Inciardi, J. A., & Goode, J. L. (2003). Miracle medicine or problem drug? OxyContin and prescription drug abuse. Consumer Research, July 2003, 17-21.
11. Jonas, A. B., Young, A. M., Oser, C. B., Leukefield, C. G, & Havens, J. R. (2012). OxyContin as currency: OxyContin use and increased social capital among rural Appalachian drug users. Social Science and Medicine, 74(10), 1602-1609.
12. Kokkevi, A., Richardson, C, Palermou, B., & Leventakou, V. (1997). Reliability of drug dependents' self-reports. Drug and Alcohol Dependence, 45(1-2), 55-61.
13. Latkin, C. A., Vlahov, D., & Anthony, J. C. (1993). Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. Addiction, 88(4), 517-526.
14. Lipman, A. G. (2003). What have we learned from OxyContin? Journal of Pain and Palliative Care Pharmacotherapy, 17(1), 1-4.
15. Muhr, T. (2010). ATLAS.ti. Berlin: Scientifc Software Development.
16. Passik, S.D. (2003). Same as it ever was? Life after the OxyContin® media frenzy. Journal of Pain and Symptom Management, 25(3), 199-201.
17. Purdue Pharma L. P. (2010). Statement of Purdue Pharma L. P. Regarding FDA's Approval of Reformulated OxyContin® (Oxycodone HCl Controlled-Release) Tablets. Retrieved from http://www.purduepharma.com/News-and-Media/News/Pages/ 20100405.aspx
18. Quintero, G, Peterson, J., & Young, B. (2006). An exploratory study of socio-cultural factors contributing to prescription drug misuse among college students. Journal of Drug Issues, 36(4), 903-932.
19. Reiger, D. A., Farmer, M. E., Rae, D. S., Locke, B. Z., Keith, S. J., Judd, L. L., et al. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Journal of the American Medical Association, 264(19), 2511-2518.
20. Rosenblum, A., Parrino, M., Schnoll, S. H., Fong, C, Maxwell, C, Cleland, C. M., et al. (2007). Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug and Alcohol Dependence, 90(1), 64-71.
21. U.S. Census Bureau. United States Census 2000. Washington, DC: U.S. Census Bureau.
22. U.S. General Accounting Office. (2003). Prescription drugs: OxyContin Abuse and Diversion and Efforts to Address the Problem. Washington, DC: U.S. General Accounting Office
23. U.S. National Drug Intelligence Center. (2004). Intelligence Bulletin: OxyContin Diversion, Availability, and Abuse. Johnstown, PA: U.S. National Drug Intelligence Center
24. U.S. National Drug Intelligence Center. (2010). Appalachia High Intensity Drug Traffcking Area: Drug Market Analysis 2010. Johnstown, PA: U.S. National Drug Intelligence Center.
25. U.S. Office of National Drug Control Policy. (2011). Epidemic: Responding to America's Prescription Drug Abuse Crisis. Washington, DC: U.S. Office of National Drug Control Policy.
26. U.S. Substance Abuse and Mental Health Services Administration. (2012). Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: U.S. Substance Abuse and Mental Health Services Administration.
27. Van Zee, A. (2009). The promotion and marketing of OxyContin: Commercial triumph, public health tragedy. American Journal of Public Health, 99(2), 221-227.
28. Webster, L. R., & Fine, P. G. (2010). Approaches to improve pain relief while minimizing opioid abuse liability. Journal of Pain, 11(7), 602-211.
29. Wolfe, S. (2010). Annual U.S. OxyContin prescriptions (millions). U.S. Food and Drug Administration. Retrieved from http://www.fda.gov/downloads/ AdvisoryCommittees/Committees Meeting Materials/Drugs/ AnestheticAndLifeSupportDrugsAd-visoryCommittee/UCM220954.pdf
30. Young, A. M., & Havens, J. R. (2012). Transition from first illicit drug use to first injection drug use among rural Appalachian drug users: A cross-sectional comparison and retrospective survival analysis. Addiction, 107(3), 587-596.